% | $
Quotes you view appear here for quick access.

Halozyme Therapeutics, Inc. Message Board

  • rainbowmeow2003 rainbowmeow2003 Oct 1, 2013 8:22 AM Flag

    It is premature to envisage the potential of PEGPH20 in pancreatic cancer

    Due to the small number of patients treated to date: While the results look intriguing, particularly
    in the patients who express high levels of HA, the number of patients is too low to draw a conclusion about clinical utility. In addition, the pancreatic cancer space is becoming increasingly competitive with the recent approval of Abraxane as well as a number of newly-initiated or ongoing Phase III studies of competing therapies. Although cross-trial comparison is fraught with many confounding factors, median survival of 8.5 months in patients treated with Abraxane/gemcitabine combination in the Phase III MPACT trial is longer than the median survival of 200 days in the Phase Ib trial of PEGPH20/gemcitabine combination.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
8.07+0.29(+3.73%)12:36 PMEDT